◀ Back to MAPK1
GP6 — MAPK1
Text-mined interactions from Literome
Dobreva et al., Immunopharmacol Immunotoxicol 2007
:
The immunomodulatory activity of C3 binding
glycoprotein ( C3bgp ) is
mediated by the complement receptor type III and
mitogen activated protein kinase signal transduction pathways
Oh et al., Naunyn Schmiedebergs Arch Pharmacol 2009
:
Our results revealed that the CTB
glycoprotein in the presence of DEHP
inhibits the translocation of PKC from cytosol to membrane and the phosphorylation of p44/42
MAPK in primary cultured T lymphocytes
Pierangeli et al., Lupus 2010
(Antiphospholipid Syndrome...) :
This review article will address the experimental and/or clinical evidence behind some of these potential ` immunomodulatory ' approaches ( tissue factor inhibition, P38
mitogen activated protein kinase inhibition , nuclear factor-kappaB inhibition, platelet
glycoprotein receptor inhibition, hydroxychloroquine, statins, inhibition of beta(2)GPI and/or anti-beta(2)GPI binding to target cells, complement inhibition, and B cell inhibition ) in antiphospholipid syndrome
Oh et al., Cell Biochem Funct 2010
:
Our results showed that the CTB
glycoprotein in the presence of DEHP
inhibits the production of intracellular ROS, the phosphorylation of ERK1/2, and p38
MAPK in HMC-1 cells
Lee et al., Naunyn Schmiedebergs Arch Pharmacol 2012
:
With regard to proliferation related signals, our finding indicated that SJSZ
glycoprotein ( 50 µg/ml )
diminished the production of intracellular ROS, activity of phosphorylated ERK, p38
MAPK , NF-?B ( p50 and p65 ), PCNA, and cyclin D1/CDK4 in MNNG induced BNL CL.2 cells